## Abstract Dopaβresponsive dystonia (DRD) is typically caused by heterozygous mutations in GTP cyclohydrolase 1 gene (__GCH1__). Our aim was to investigate the clinical and genetic features of Chinese DRD patients. We analyzed a cohort of Chinese DRD patients' clinical data. Mutation of the __GCH1
Novel GCH1 mutation in a Brazilian family with dopa-responsive dystonia
β Scribed by Sarah Teixeira Camargos; Francisco Cardoso; Parastoo Momeni; Juliana Gurgel Gianetti; Andrew Lees; John Hardy; Andrew Singleton
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 78 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Dopa responsive Dystonia (DRD) was first described in 1971 and typically begins at childhood with gait dysfunction caused by foot dystonia progressing to affect other extremities. There is marked diurnal fluctuation and sustained improvement of symptoms with low dose levodopa therapy. Heterozygous mutation of the gene GCH1 has been shown to cause DRD. We studied GCH1 in nine patients with DRD from six families of Federal University of Minas Gerais Movement Disorders Clinic. We identified three mutations; two affected siblings carried a novel T209P mutation and two siblings from another family were compound heterozygous carriers of Met211Val and Lys224Arg mutations. To our knowledge this is the first report of GCH1 mutations underlying DRD in patients from Brazil. Β© 2007 Movement Disorder Society
π SIMILAR VOLUMES
## Abstract We describe the clinical and molecular correlates in two Italian families with dopaβresponsive dystonia (DRD) and the same novel mutation of GTPβcyclohydrolase I (GCHβI) gene. Thirtyβfive subjects were examined and the genotype correlated to phenotype. Childhood onset foot dystonia is p
## Abstract We report the clinical and molecular features of a family with focal hand dystonia caused by DYT1 mutation. Four members of a family who underwent thalamotomy showed a marked and sustained therapeutic benefit that lasted for up to 12 years without recurrence of dystonia or any significa